Pretreatment with recombinant murine tumor necrosis factor alpha/cachectin and murine interleukin 1 alpha protects mice from lethal bacterial infection by unknown
PRETREATMENT WITH RECOMBINANT MURINE TUMOR
NECROSIS FACTOR cdCACHECTIN AND MURINE
INTERLEUKIN 1 a PROTECTS MICE FROM
LETHAL BACTERIAL INFECTION
BY A. S. CROSS, J. C. SADOFF, N. KELLY, E. BERNTON, AND P. GEMSKI
From the Departments of Bacterial Diseases, Molecular Pathology and the Division of
Neuropsychiatry, Walter Reed Army Institute of Research, Washington, DC 20307
Tumor necrosis factor a/cachectin(TNF/C) is a well-characterized peptide (1) that
may, through its diverse effects on cells, mediate many normal host functions, in-
cluding tissue remodeling and the mobilization of energy reserves required by the
infected host (2). In contrast to such beneficial effects, TNF/C has also been shown
to have adverse effects on the animal host. It is a principal mediator of the toxic
effects of LPS and an important mediator in murine cerebral malaria (3-5). Be-
causeofits toxic effects, TNF/C is generallyconsidered to be an abnormal and dele-
terious responsethat plays little ifany rolein host defense against bacterial infection
and thus has been considered as atarget for therapeutic intervention to ameliorate
host toxic responses (4, 6). Based on these considerations, one might expect that
animals thatare unable toproduce TNF/C in response tobacterial endotoxin would
be more resistant to lethal infection than animals that are able to produce TNF/C.
The C3H/HeJ mouse is unable to produce TNF/C directly in response to LPS,
whereas its congenic pair, the C3H/HeN mouse, does (7). Therefore, we reasoned
that the C3H/HeJ mouse would be more resistant than the C3H/HeN mouse to
lethal infectionwith virulent Gram-negative bacteria capable ofcausing bacteremic
infection and septic shock. In this study we show, however, thatthe C3H/HeJ mouse
is more susceptible to lethal infection with K1-encapsulated Escherichia coli than is
theC3H/HeN mouse, and thatpretreatment ofC3H/HeJ micewith a combination
ofrecombinant murine TNF/C and recombinant murine IL-la protects thesemice
from infection with an inoculum of >20 LD5o.
Materials and Methods
E. coli 018:K1:H7, strain Bort, is an isolate retrieved from the spinal fluid ofa neonate
with meningitis. It is insensitive to lysis by rough LPS-specific phages (8) and, as a smooth
organism, produces O-side chains as shown by SDS-PAGE. We selected a Kl- mutant of
this strain as a clone resistant to lytic K1 phages, as recently described (8).
C3H/HeJmicewereobtained fromTheJacksonLaboratories, BarHarbor, ME. C3H/HeN
micewere obtained from theSmallAnimal Section, NationalInstitutesofHealth, Bethesda,
MD. Both strains of mice, all females, were used between 9 and 12 wk of age. LD5o deter-
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minations were performed by randomly assigning six mice per group, with each given 10-fold
dilutions of bacterial suspensions in volumes of 0.1 ml intraperitoneally. LPS was made by
the hot phenol water extraction method. Animals were followed for up to 30 d before ter-
minating the experiment; however, deaths rarely occurred after day 7 .
The C3H/HeJ mice were given a single intraperitoneal injection of recombinant murine
TNF/C-a (lot no. B8120; 4 x 10' U/mg sp act; Genzyme, Boston, MA) and/or murine rIL-
la (106 U/mg sp act; kindly provided by Dr. Peter Lomedico, Hoffman-LaRoche, Inc.,
Nutley, NJ) just before challenge with E. coli. Dilution of the recombinant cytokines was
made in pyrogen-free normal saline. There was 0.12 EU/ml of endotoxin contamination in
the rTNF and <0.125 EU/ml in the rIL-1 as measured in the limulus assay.
TNF/C activity was assessed by the colorometric determination of cytotoxicity to L 929
cells, as previously described (9, 10). For preparation of a standard curve, murine rTNF/C
was added to normal mouse serum at concentrations of 400 ng/ml to 5.12 pg/ml. The serum
was obtained from CD-1 mice (Charles River Breeding Laboratories, Wilmington, MA) and
kept at -20°C until use. The standards and test sera were then heat inactivated at 56°C
for 30 min before beingassayed for TNF/C. TNF/C was not inactivated by the heating, which
concurs with data provided by the manufacturer. A standard curve was constructed by graphing
optical density versus concentration of TNF/C in the standards. 50% cytotoxicity (i.e., 1 U
of TNF/C activity) was observed with -25 pg of the standard TNF/C.
Production of TNF/C in C3H mice was accomplished by priming mice with 100 J1 of a
1 :10 dilution ofBCG injected intraperitoneally (kindly supplied by Dr. Carol Nacy, WRAIR,
which she obtained from the Trudeau Institute, Saranac Lake, NY). 7-10 d later mice were
given a nonlethal, intravenous dose ofLPS prepared -from the Bort strain of E. coli and bled
2 h later. Murine serum was kept at -70°C until assayed for TNF/C.
Results
In comparing the LD50 of this clinical isolate for the two strains of mice, Bort
was highly virulent to the C3H/HeJ mouse in which TNF/C production is blocked
(Table I). Less than 10 organisms were required to kill these mice. In contrast, mice
that produce TNF/C in response to LPS (C3H/HeN) required 103 times more bac-
teria to achieve lethal infection. This occurred in spite of the fact that purified LPS
from this E. coli strain was 10-fold less potent in killing the C3H/HeJ mice (Table
I) . With the less virulent Kl - mutant these differences in host infection doses were
not seen. These findings suggest that TNF/C, in contrast to being solely a delete-
rious factor in host infection, may participate in stimulating important host defense
mechanisms against infection with virulent organisms, as has been previously specu-
lated (2).
To test this hypothesis, we pretreated C3H/HeJ mice with either normal saline
or rTNF/C. In addition, because of previous reports of synergistic activity with com-
binations of IL-1 and TNF/C (11, 12), we also treated mice with IL-1 alone and in
TABLE I
Susceptibility of LPS-responsive C3H/HeN and LPS-hyporesponsioe
C3HIHe,J Mice to E. coli 018:Kl:H7, Strain Bort, and Its LPS
Intraperitoneal challenge.
LD5o'
C3H/HeN C3H/HeJ
018 LPS400 400 ug 3,750 ug
E. coli 018:K1' 104 CFU <10' CFU
E. coli 018:K1 - 107 CFU 107 CFUCROSS ET AL.
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combination with TNF/C immediately before challenge with the virulent E. coli.
All saline-treated mice died after infection with as little as 19 CFU. For challenges
of 85 and 193 CFU, TNF/C alone (with doses of 1 or 10 Fig/kg) andIL-1 (with doses
from 500 to 5,000 U per mouse) provided transient protection at day 2, but this
effect was lost by day 3 (Table II). In contrast, mice pretreated with a combination
of 1 Ag/kg TNF/C and 500 U of IL-1 were significantly protected from lethal infec-
tion. This combination provided transient protection at >100 LD5o (2/5 mice chal-
lenged with 1,930 CFU alive at day 2 vs. 0/5 challenged with 19 CFU [data not
shown]), and 80% protection at >20 LD5o at day 7 (Table II). Mice alive at day
7 remained healthy and active through day 30, at which time the experiment was
terminated. Underthese experimental conditions TNF/C andIL-1 were unable, how-
ever, to protect fully the C3H/HeJ mouse against 104 organisms, which is the LD50
for theC3H/HeN mouse (Table I). The combination ofTNF/C at 1 hg/kg and IL-1
at 1,000 U was a less effective combination, with transient protection observed only
in Exp. 1, with a bacterial challenge of 85 CFU. Culture of both blood and liver
revealed recovery of strain Bort (107 CFU/g tissue and per milliliter blood at 48 h),
which indicated that infection resulting from the challenge was the cause of death
in these animals. Neitherdeath nor symptoms of sepsis (lethargy, piloerection, diar-
rhea) were noted after IL-1 administration up to 10,000 U.
A nonlethal dose of LPS (10 kg) given intravenously to BCG-primed C3H/HeN
mice induced detectable levels ofcirculating TNF/C within 2 h. Levels of300-3,000
pg/ml serum were detected in all mice so challenged. In contrast, no circulating TNF/C
was detected in C3H/HeJ mice similarly given 10 jig LPS. TNF/C was detected in
C3H/HeJ mice, however, when given >400 fig of LPS intravenously. Four C3H/HeN
TABLE II
Survival of C3H/HeJ Mice Pre-treated Concurrently with Mouse rTNF-a,
rIL-1u Either Alone or in Combination vs. Untreated Controls Challenge
Intraperitoneally with Atleast 10 LD5o of E. coli 018:KI:H7
Pretreatment
a. None
b. TNF (1 Wg/kg)
c. TNF (10 Wg/kg)
d. IL-1 (500 U)
e. IL-1 (1,000 U)
f. IL-1 (500 U) + TNF (1 jig/kg)
g. IL-1 (1,000 U) + TNF (1 jLg/kg)
Bacterial challenge in Exp. 1 was 85 CFU/mouse (-10 LD5o) and in Exp. 2
was 193 CFU (-20 LD5o). In Exp. 2 a control group of five mice received
19 CFU and all died (not shown).
$ Values shown are the survivors per total number in original group tested at
days 2 and 7 after bacterial challenge.
§ Data were tested for statistical significance in the Kruskal-Wallis test for rank
sums and groups were analyzed for two-tailed multiple comparisons by the
method of Dunn (28). p < 0.020, Exp . 1 : fvs. e; Exp. 2 : fvs. g; p < 0 .005,
Exp. I : fvs. a,b ; Exp. 2: fvs. a; p < 0.00005, Exp. 1 : fvs. a. All other com-
parisons did not achieve statistical significance.
Exp .
Day 2
1'
Day 7
Exp.
Day 2
2`
Day 7
2/7t 0/7 0/5 0/5
4/7 1/7 3/5 0/5
5/5 0/5 1/2 0/2
7/7 0/7 0/3 0/3
6/7 1/7 1/3 0/3
7/7 7/7§ 6/6 5/6§
4/4 0/4 0/6 0/62024
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mice that had not been previously primed with BCG were given 10 LD5o of strain
Bort viathe intraperitoneal route. At 20-22 h all four mice appeared moribund (ex-
treme lethargy, tachypnea, piloerection, and closed eyes) and had -108 CFU/ml cir-
culating in their serum. None of these mice had detectable TNF/C in their serum.
Four C3H/HeJ mice were also given 10 LD5o of strain Bort intraperitoneally. These
mice appeared moribund 29-44 h after bacterial challenge and also had -108
CFU/ml circulating in theirserum. As in the case of theC3H/HeNmice, the C3H/HeJ
mice had no detectable TNF/C in their serum. In these assays, the serum from the
BCG-primed C3H/HeN mice that were given LPS served as positive controls for
the presence of TNF/C.
Discussion
TNF/C is considered to be the principalmediator of endotoxic shock(2, 3). When
given to animals in quantities found to be produced endogenously in response to
endotoxin, rTNF/C has been shown to produce shock and death, which is similar
to that seen after bacteremia with Gram-negative bacilli (2-4). Furthermore, anti-
body against TNF/C can block the effects of endotoxin administered in vivo (6).
In some animal models these antiTNF/C antibodies, when administered before in-
fection, can blockthe lethal effects of Gram-negative bacteremia induced by the in-
jection of large numbers of bacteria (13). Therefore, antibodies and pharmacologic
agents directed against TNF/C have become attractive candidates for prevention
of septic shock in humans (4, 6). In this study we show that TNF/C in conjunction
with IL-1 at low doses has a significant protective role in invasive infections that
require bacterial replication and translocation in the host.
When a relatively avirulent mutant of E. coli was tested in the two mouse strains,
there were no differences in LD5o (Table I). Therefore, the defense mechanisms in
which TNF/C may be involved appear less important for organisms of relatively
low virulence and which may be easily killed by non-cytokine-mediated host defenses.
In this situation TNF/C may manifest itself as a deleterious mediator; the use of
antiTNF/C antisera in animal models infected with these types of bacteria would
be expected to show a protective effect. Such models, however, may be more an ex-
perimental expression of endotoxemia than of natural infection. For example, in
the baboon shockmodel(13), antiTNF/C mAbgivenprophylactically protectedagainst
septic shock induced with 1011 E. coli per kilogram. Although the virulence prop-
erties of this E. colt are not specified beyond its serotype (086 :137), the large challenge
inoculum implies that the organism has relatively low virulence. In our studies, we
have shown that after an inoculum ofas little as 19-85 CFU into the C3H/HeJmouse
(i.e., an inoculum of E. colt that is >107-fold less perweight of animal), the parental
Kl-encapsulated E. colt replicates and disseminates through the host where it achieves
a level of 107 CFU/g of liverjust before the death of the mouse. The virulence prop-
erties ofbacteria that require the host to respondwith cytokine-mediated host defenses
remain to be defined.
The observation that TNF/C and IL-1 provided significant protection only when
used in combination suggests there may be a synergism between their individual
activities. Alternatively, these cytokines may be more efficient together in inducing
the release of other mediators, such as has been shown in the induction of GSFs
(11). One speciesof CSF, granulocyte/macrophage activating factor (GM-CSF), likeCROSS ET AL.
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TNF/C (14), is also a potent activator of phagocytes (15). There have now been
numerous studies demonstrating that rIL-1, rIL-2, and IFN-(3, when given alone,
protect animals from lethal infection by intracellular bacteria (e.g., listeria) and by
bacteria not usuallyconsidered to be controlled by the cellular immune system (e.g.,
Klebsiella spp., Pseudomonas aeruginosa) (16-18). In these studies, the participation of
other unknown cytokines or mediators is inferred since, in the case of IL-1 and 2,
there is neither a direct bactericidal effect on the organism nor on the activation
of phagocytes (16). In our study we used a strain of mouse (C3H/HeJ) that is less
able to produce both TNF/C and IL-1 in response to LPS than is the C3H/HeN
mouse (10 Ag of LPS induced detectable TNF/C in the latter mouseversus >400 Fig
LPS in the C3H/HeJ mouse). Our finding that the combination of cytokines, at
appropriate doses, protects the C3H/HeJ mouse from lethal infection is consistent
with the hypothesis that TNF/C, a potent activator of phagocytes, participates in
the normal IL-1- or IL-2-mediated protection. An important role forTNF/C in host
resistance to infection with Listeria monocytogenes was suggested by the enhancement
of lethal infection after pretreatment with antiTNF/C antibody (19).
Our finding in separate experiments that doubling the dose of IL-1 abrogates the
protective effect of a comination dose demonstrates in vivo that, to achieve protec-
tion during naturalinfection, there must be controlled regulation ofthese cytokines.
This is consistent with past observations of TNF/C (7). In cell culture TNF/C and
IL-1 are each able to induce more IL-1 (20, 21). In addition, other cytokines that
are induced by TNF/C may in turn induce more TNF/C (22). As little as 200 ng/g
or 5 ttgof TNF/C hasbeen shown to adversely affect rodents (3, 23) and a combina-
tion of these cytokines does cause tissue damage (24). Consequently, our observa-
tion that the mice treated with the low doses of TNF/C and IL-1 remain healthy
and active demonstrates that such toxic levels of TNF/C were not achieved and that
these positive feedback loops were not activated.
Our results suggest that the host response mediated by TNF/C and IL-1 to LPS
may be a potent stimulus to protective mechanisms against infection with highly
virulent, invasive organismscapable of causingbacteremia and septic shockin man.
Increases in TNF/C may be a normal response to bacterial invasion. Even with the
induction of a nonlethal elevation of circulating TNF/C in BCG-primed mice, host
regulatory mechanisms appeared to mitigate the potential adverse effects of this
cytokine. In this light, TNF/C-mediated septic shock may be dueto abnormal regu-
lation of a normal response. The data that moribund mice with high levels of bac-
teria circulating in theblood do nothave detectable TNF/C differs from the findings
of circulating TNF/C close to death during meningococcal infection in man (25)
and during murine cerebral malaria (5). These data suggest that if an abnormal
TNF/C response is an important component of septic shock in C3H mice, the ki-
netics of its release and regulation are different from these latter infections.
Previous investigations have suggested that TNF/C-mediated responses may be
important in host defenses against parasitic infection (26, 27), and that the combi-
nation of TNF/C and IL-1 protects against radiation-induced death (23). The dele-
terious, potentially fatal side effects ofTNF/C are well recognized. Nonetheless, our
experimental findings now reveal aneed forcautionbefore use of antiTNF/C agents,
which when used in a prophylactic mode might interfere with important TNF/C
host-stimulated defenses.2026
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Summary
Tumor necrosis factor/cachectin (TNF/C) is the principal mediator of bacterial
endotoxin-induced shock and death. We found that the C3H/HeJ mouse, which
is less able to produce TNF/C in response to endotoxin, has a 1,000-fold greater
susceptibility to lethal infection with Escherichia coli than the TNFresponsive con-
genic mouse, C3H/HeN. This surprising finding suggested that this lethal peptide
may also be involved in host protection. To test this hypothesis we pretreated the
C3H/HeJ mouse with a combination of recombinant murine TNF/C-a and IL-1a.
This combination protected these mice against an intraperitoneal bacterial challenge
of >20 LD5os (nearly 2 x 102 CFU) that grew to a level of >10' CFU/ml of blood
and per gram of liver in untreated mice. This suggests a significant role for these
cytokines in host defenses against invasive infections that require bacterial replica-
tion within the host. These protective mechanisms may not be important for less
virulent organisms. These findings may have important implications for the pro-
posed use of antiTNF/C agents in the treatment of septic shock.
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